US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Odyssey Therapeutics

19.02

+0.89504.94%

Volume:266.51K

Turnover:5.11M

Market Cap:913.32M

PE:-5.69

High:19.64

Open:18.72

Low:18.49

Close:18.12

52wk High:29.05

52wk Low:15.10

Shares:48.03M

Float Shares:13.24M

Volume Ratio:0.97

T/O Rate:2.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.3410

EPS(LYR):-50.1297

ROE:-85.50%

ROA:-41.66%

PB:2.17

PE(LYR):-0.38

Loading ...

Overview Company News Filings

Odyssey Therapeutics initiated with an Outperform at Raymond James

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for Od-001 in Ulcerative Colitis at Ueg Week 2026

THOMSON REUTERS

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

H.C. Wainwright Keeps Their Buy Rating on Odyssey Therapeutics, Inc. (ODTX)

Odyssey Therapeutics to Present at Stifel Virtual Immunology and Inflammation Forum

HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target

MT Newswires Live

Odyssey Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $44

THOMSON REUTERS

Odyssey Therapeutics to Participate in Upcoming Investor Conferences

Odyssey Therapeutics is Maintained at Overweight by JP Morgan

Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)

Evotec Partners with Odyssey Therapeutics on AI-Enabled Autoimmune, Inflammatory Drug Discovery

Odyssey Therapeutics Q2 FY26 Net Loss Widens to $52.8 Million

Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS

HBM Healthcare Says Lilly to Buy Portfolio Company Curevo Vaccine

Tyler Van Buren Initiates Buy on Odyssey Therapeutics Citing Strong OD-001 Phase IIa Data, Novel RIPK2 Mechanism, and Emerging Pipeline Optionality

Odyssey Therapeutics Price Target Maintained With a $40.00/Share by Oppenheimer

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)

Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate

Benzinga Earnings

Odyssey Therapeutics Q1 FY26 net loss narrows to $38.3 million; R&D expenses fall 16.75% to $32.3 million

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/ODTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","market":"US","secType":"STK","nameCN":"Odyssey Therapeutics","latestPrice":19.015,"timestamp":1791575929712,"preClose":18.12,"halted":0,"volume":266513,"delay":0,"changeRate":0.04939293598233993,"floatShares":13240000,"shares":48031300,"eps":-3.341,"marketStatus":"Trading","change":0.895,"latestTime":"10-09 15:58:51 EDT","open":18.72,"high":19.64,"low":18.49,"amount":5113230.202197,"amplitude":0.063466,"askPrice":19.08,"askSize":173,"bidPrice":19,"bidSize":468,"shortable":3,"etf":0,"ttmEps":-3.341,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"listingDate":1778212800000,"exchange":"NASDAQ","adjPreClose":18.12,"preHourTrading":{"tag":"盘前","latestPrice":19.05,"preClose":18.12,"latestTime":"09:18 EDT","volume":142,"amount":2714.09996,"timestamp":1791551932761,"change":0.93,"changeRate":0.051325,"amplitude":0.059051},"postHourTrading":{"tag":"盘后","latestPrice":18.12,"preClose":18.12,"latestTime":"19:30 EDT","volume":1272,"amount":23031.26,"timestamp":1791502204065,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.965713},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODTX\",,,,,undefined,":{"symbol":"ODTX","floatShares":13240000,"roa":"-41.66%","roe":"-85.50%","lyrEps":-50.129685,"volumeRatio":0.965713,"shares":48031300,"dividePrice":0,"high":19.64,"amplitude":0.063466,"preClose":18.12,"low":18.49,"week52Low":15.1,"pbRate":"2.17","psRate":"9225.41","week52High":29.05,"institutionHeld":0,"latestPrice":19.015,"committee":0.460218,"eps":-3.341,"divideRate":0,"volume":266513,"delay":0,"ttmEps":-3.341,"open":18.72,"prevYearClose":18,"prevWeekClose":20.725,"prevMonthClose":22.22,"prevQuarterClose":22.22,"fiveDayClose":20.725,"twentyDayClose":24.63,"sixtyDayClose":17.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"ODTX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODTX","date":"2026-10-08","current":-5.69141,"percent":0.836538,"low":-8.61189,"twenty":-6.929038,"median":-5.955971,"eighty":-5.4285,"high":-5.017591,"avg":-6.165306,"sd":0.813997,"marketCap":866365738},"quantilePoints":[{"date":"2026-05-08","current":-5.722186,"twenty":-5.722186,"median":-5.722186,"eighty":-5.722186,"marketCap":850585842},{"date":"2026-05-15","current":-5.496622,"twenty":-5.693383,"median":-5.609284,"eighty":-5.496622,"marketCap":817056381},{"date":"2026-05-22","current":-5.629912,"twenty":-5.680689,"median":-5.537878,"eighty":-5.38396,"marketCap":836869527},{"date":"2026-05-29","current":-5.687036,"twenty":-5.681958,"median":-5.553746,"eighty":-5.441085,"marketCap":845360875},{"date":"2026-06-05","current":-5.395068,"twenty":-5.640067,"median":-5.507729,"eighty":-5.381104,"marketCap":801960652},{"date":"2026-06-12","current":-5.33477,"twenty":-5.599446,"median":-5.433151,"eighty":-5.365236,"marketCap":792997562},{"date":"2026-06-18","current":-5.864756,"twenty":-5.646414,"median":-5.455366,"eighty":-5.369045,"marketCap":871778402},{"date":"2026-06-26","current":-5.739918,"twenty":-5.704904,"median":-5.528358,"eighty":-5.374757,"marketCap":852228560},{"date":"2026-07-02","current":-5.356182,"twenty":-5.790223,"median":-5.545812,"eighty":-5.374122,"marketCap":795253729},{"date":"2026-07-10","current":-5.427125,"twenty":-5.732825,"median":-5.496622,"eighty":-5.359042,"marketCap":805786891},{"date":"2026-07-17","current":-5.501292,"twenty":-5.710665,"median":-5.510065,"eighty":-5.36714,"marketCap":816798833},{"date":"2026-07-24","current":-5.697997,"twenty":-5.732825,"median":-5.553746,"eighty":-5.374122,"marketCap":846004419},{"date":"2026-07-31","current":-5.939848,"twenty":-5.856557,"median":-5.572788,"eighty":-5.377217,"marketCap":881912925},{"date":"2026-08-07","current":-6.447481,"twenty":-5.942427,"median":-5.59659,"eighty":-5.382058,"marketCap":1031771093},{"date":"2026-08-14","current":-6.204393,"twenty":-6.026914,"median":-5.668975,"eighty":-5.382691,"marketCap":992870470},{"date":"2026-08-21","current":-7.387181,"twenty":-6.093162,"median":-5.678649,"eighty":-5.386182,"marketCap":1182148383},{"date":"2026-08-28","current":-7.779447,"twenty":-6.206789,"median":-5.687036,"eighty":-5.395703,"marketCap":1244921564},{"date":"2026-09-04","current":-7.905212,"twenty":-6.445274,"median":-5.710091,"eighty":-5.402083,"marketCap":1265047317},{"date":"2026-09-11","current":-7.078758,"twenty":-6.638581,"median":-5.780226,"eighty":-5.417451,"marketCap":1132792370},{"date":"2026-09-18","current":-6.952993,"twenty":-6.952993,"median":-5.846332,"eighty":-5.42363,"marketCap":1112666617},{"date":"2026-09-25","current":-5.967836,"twenty":-6.988926,"median":-5.907601,"eighty":-5.427125,"marketCap":955014887},{"date":"2026-10-02","current":-6.114561,"twenty":-6.952993,"median":-5.955971,"eighty":-5.433151,"marketCap":978494932},{"date":"2026-10-08","current":-5.413872,"twenty":-6.929038,"median":-5.955971,"eighty":-5.4285,"marketCap":866365738}],"updateTime":1791575931408},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674000502","title":"Odyssey Therapeutics initiated with an Outperform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000502?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:10","pubTimestamp":1791490230,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Odyssey Therapeutics (ODTX) with an Outperform rating and $42 price target Odyssey’s lead asset OD-001 is in Ph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/odyssey-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/odyssey-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027055","title":"Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for Od-001 in Ulcerative Colitis at Ueg Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673027055?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nTUA8CP1DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673601056","title":"Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673601056","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673601056?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288000,"startTime":"0","endTime":"0","summary":"Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct.  06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“O","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/06/3375422/0/en/odyssey-therapeutics-announces-oral-presentation-of-additional-phase-2a-induction-data-for-od-001-in-ulcerative-colitis-at-ueg-week-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669670621","title":"H.C. Wainwright Keeps Their Buy Rating on Odyssey Therapeutics, Inc. (ODTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669670621","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669670621?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:56","pubTimestamp":1790013387,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Odyssey Therapeutics, Inc. today and set a price target of $44.00. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-odyssey-therapeutics-inc-odtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-odyssey-therapeutics-inc-odtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667435988","title":"Odyssey Therapeutics to Present at Stifel Virtual Immunology and Inflammation Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2667435988","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667435988?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:01","pubTimestamp":1789560099,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics to present at Stifel Virtual Immunology and Inflammation ForumOdyssey Therapeutics will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Sept. 23 at 11:00 a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL9NPGKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","SF","SG9999014021.USD","BK4112","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","NDAQ","BK4585","LU2095319765.USD","BK4588","BK4139","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","BK4127","ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701047","title":"HC Wainwright Initiates Odyssey Therapeutics at Buy With $44 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701047","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662701047?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:33","pubTimestamp":1787830439,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics, Inc. (ODTX) has an average rating of buy and mean price target of $35.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703638","title":"Odyssey Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703638?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:12","pubTimestamp":1787825531,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nAZN4TGPAB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662719875","title":"Odyssey Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2662719875","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662719875?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:00","pubTimestamp":1787745600,"startTime":"0","endTime":"0","summary":"BOSTON, Aug.  26, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351300/0/en/odyssey-therapeutics-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657409156","title":"Odyssey Therapeutics is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2657409156","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657409156?lang=en_us&edition=fundamental","pubTime":"2026-08-08 00:26","pubTimestamp":1786119960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODTX/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657168448","title":"Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657168448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657168448?lang=en_us&edition=fundamental","pubTime":"2026-08-06 17:50","pubTimestamp":1786009833,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biodesix (BDSX), Pacific Biosciences (PACB) and Odys...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biodesix-bdsx-pacific-biosciences-pacb-and-odyssey-therapeutics-inc-odtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biodesix-bdsx-pacific-biosciences-pacb-and-odyssey-therapeutics-inc-odtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HCSG","BK4588","BDSX","BK4139","PACB","BK4121","BK4137","ODTX","LABU","BK4196","BK4581","LU0029874061.USD","LU0128526141.USD","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657350454","title":"Evotec Partners with Odyssey Therapeutics on AI-Enabled Autoimmune, Inflammatory Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2657350454","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657350454?lang=en_us&edition=fundamental","pubTime":"2026-08-06 13:37","pubTimestamp":1785994621,"startTime":"0","endTime":"0","summary":"Evotec partners with Odyssey Therapeutics on AI-enabled autoimmune, inflammatory drug discoveryEvotec entered a strategic R&D collaboration with Odyssey Therapeutics to discover new small-molecule tre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL67DT4Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656353028","title":"Odyssey Therapeutics Q2 FY26 Net Loss Widens to $52.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656353028","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656353028?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:07","pubTimestamp":1785841662,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics Q2 FY26 net loss widens to $52.8 millionOdyssey Therapeutics posted a GAAP net loss of $52.8 million in Q2 2026, widening from a $41.2 million loss a year earlier.R&D expense rose","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL5r3cYf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656053039","title":"Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656053039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656053039?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUADWSG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653922705","title":"HBM Healthcare Says Lilly to Buy Portfolio Company Curevo Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2653922705","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653922705?lang=en_us&edition=fundamental","pubTime":"2026-07-24 12:42","pubTimestamp":1784868170,"startTime":"0","endTime":"0","summary":"HBM Healthcare says Lilly to buy portfolio company Curevo VaccineHBM Healthcare Investments reported a CHF 238 million Q1 FY 2026/27 profit, driven by CHF 183 million gains in listed holdings.Private ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL4XjwC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBLS","ODTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644385390","title":"Tyler Van Buren Initiates Buy on Odyssey Therapeutics Citing Strong OD-001 Phase IIa Data, Novel RIPK2 Mechanism, and Emerging Pipeline Optionality","url":"https://stock-news.laohu8.com/highlight/detail?id=2644385390","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644385390?lang=en_us&edition=fundamental","pubTime":"2026-06-19 01:15","pubTimestamp":1781802919,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ODTX stock, giving a Buy rating today. Tyler Van Buren has given his Buy ra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tyler-van-buren-initiates-buy-on-odyssey-therapeutics-citing-strong-od-001-phase-iia-data-novel-ripk2-mechanism-and-emerging-pipeline-optionality-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tyler-van-buren-initiates-buy-on-odyssey-therapeutics-citing-strong-od-001-phase-iia-data-novel-ripk2-mechanism-and-emerging-pipeline-optionality-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","LU1989773731.SGD","BK4585","BK4139","LU1989763005.USD","LU0390134368.USD","BK4588","ODTX","TYL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644868038","title":"Odyssey Therapeutics Price Target Maintained With a $40.00/Share by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2644868038","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644868038?lang=en_us&edition=fundamental","pubTime":"2026-06-19 01:11","pubTimestamp":1781802660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 13:11 ET (17:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX","OPY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083226","title":"Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083226?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:20","pubTimestamp":1781785235,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-odyssey-therapeutics-inc-odtx-capricor-therapeutics-capr-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-odyssey-therapeutics-inc-odtx-capricor-therapeutics-capr-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0432979614.USD","IE00BFXG1179.USD","BK4137","LABU","XLV","IE00BQXX3D17.EUR","LU2089283258.USD","LU1116320737.USD","LU1116320901.HKD","IE00BVYPNV92.GBP","LU2112291526.USD","LU1506573853.SGD","LU0265550359.USD","IE000M9KFDE8.USD","LU0211326839.USD","LU0265550946.USD","IE00BQXX3F31.USD","LU0314106906.USD","LU1061106388.HKD","MDT","BK4585","IE00BVYPNW00.USD","ODTX","XBI","LU1571399168.USD","LU0976567544.SGD","LU0072461881.USD","IE00B3T34201.USD","LU2028103732.USD","LU0106261372.USD","LU1023059063.AUD","LU2089984988.USD","LU0006306889.USD","HCSG","LU0496365809.HKD","LU2271345857.HKD","LU1057294990.SGD","LU2111349929.HKD","LU0029874061.USD","BK4566","BK4533","LU1989764748.USD","CAPR","LU0211331839.USD","LU0208291251.USD","LU1244550494.USD","LU0070302665.USD","LU0162691827.USD","LU1244550221.USD","LU1989764664.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644243827","title":"Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2644243827","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644243827?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:53","pubTimestamp":1781729603,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(6.77) per share which missed the analyst consensus estimate of $(1.13) by 499.12 percent. This is a 82.8 percent increase over losses of $(39.37) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/53265209/odyssey-therapeutics-q1-eps-6-77-misses-1-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644729713","title":"Odyssey Therapeutics Q1 FY26 net loss narrows to $38.3 million; R&D expenses fall 16.75% to $32.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644729713","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644729713?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727339,"startTime":"0","endTime":"0","summary":"Odyssey Therapeutics posted a net loss of $38.3 million in Q1 2026, roughly in line with the $38.4 million loss a year earlier.R&D expense fell 16.75% to $32.3 million, while G&A expense dipped 7.5% to $7.4 million.Cash, cash equivalents and marketable securities totaled $175.7 million at March 31; pro-forma cash rose to $464.4 million after IPO proceeds.The company expects its cash runway to extend into the second half of 2028.OD-001 Phase 2a ulcerative colitis data showed 27% clinical remission and 61% clinical response; Phase 2b and combo studies targeted for H2 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLGhGNd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4112","BK4139","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD","BK4588","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","ODTX","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644292407","title":"Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2644292407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644292407?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUA29XCMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ODTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":43,"code":"91000000","status":"200"}]}}